1
|
Jiang C, Pan T, Jiang Y, Zhang Z, Zeng M, Sun S, Li Z, Wu Y, Qiu J, Niu M, Gu X. Design and evaluation of dibenzoazepine-tetrahydroisoquinoline hybrids as potential P-glycoprotein inhibitors against multidrug resistant K562/A02 cells. Eur J Med Chem 2023; 249:115150. [PMID: 36708676 DOI: 10.1016/j.ejmech.2023.115150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Revised: 01/09/2023] [Accepted: 01/23/2023] [Indexed: 01/27/2023]
Abstract
Multidrug resistance (MDR) caused by P-glycoprotein (P-gp) is a main barrier to the success of cancer chemotherapies. In this study, fourteen novel dibenzoazepine-tetrahydroisoquinoline hybrids were prepared as potential P-gp inhibitors to surmount MDR caused by P-gp. Amongst them, 8a displayed the most potent inhibition effect on P-gp, thus effectively reversing P-gp-mediated drug resistance with a reversal fold (RF) value of 93.17 in K562/A02 cells. Excitingly, the EC50 value of 8a on MDR reversing effect was 48.74 nM, which was nearly two thousand-fold lower than its IC50 value (95.94 μM) for intrinsic cytotoxicity on K562/A02 cells. Further investigation showed that 8a exerted the MDR reversal effect through impairing P-gp function rather than affecting its expression. Molecular docking and CETSA results illustrated that 8a possessed a relatively high affinity for P-gp, thus effectively improving the stability of P-gp. Furthermore, 8a exhibited a much poorer inhibitory effect on CYP3A4 activity than CYP3A4 inhibitor ketoconazole, thus might not cause unfavorable drug-drug interactions. These data together suggested that 8a may be a promising lead to design P-gp inhibitors, and warranted further investigation on overcoming P-gp-mediated MDR.
Collapse
Affiliation(s)
- Chunyu Jiang
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Ting Pan
- Blood Diseases Institute, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Yunxiang Jiang
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Zhiyu Zhang
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Meifeng Zeng
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Shuang Sun
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Zheng Li
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Yiqing Wu
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Jingying Qiu
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China
| | - Mingshan Niu
- Blood Diseases Institute, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China; Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
| | - Xiaoke Gu
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221004, People's Republic of China.
| |
Collapse
|
2
|
Nobili S, Lapucci A, Landini I, Coronnello M, Roviello G, Mini E. Role of ATP-binding cassette transporters in cancer initiation and progression. Semin Cancer Biol 2020; 60:72-95. [PMID: 31412294 DOI: 10.1016/j.semcancer.2019.08.006] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2019] [Revised: 08/07/2019] [Accepted: 08/07/2019] [Indexed: 12/18/2022]
|
3
|
Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers. Eur J Med Chem 2019; 182:111655. [DOI: 10.1016/j.ejmech.2019.111655] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Revised: 08/26/2019] [Accepted: 08/27/2019] [Indexed: 12/23/2022]
|
4
|
Dei S, Romanelli MN, Manetti D, Chiaramonte N, Coronnello M, Salerno M, Teodori E. Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR). Bioorg Med Chem 2018; 26:50-64. [DOI: 10.1016/j.bmc.2017.11.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 11/06/2017] [Accepted: 11/09/2017] [Indexed: 10/18/2022]
|
5
|
Teodori E, Dei S, Coronnello M, Floriddia E, Bartolucci G, Manetti D, Romanelli MN, Santo Domingo Porqueras D, Salerno M. N -alkanol- N -cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy. Eur J Med Chem 2017; 127:586-598. [DOI: 10.1016/j.ejmech.2017.01.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Revised: 01/09/2017] [Accepted: 01/12/2017] [Indexed: 11/29/2022]
|
6
|
Gu X, Huang Z, Ren Z, Tang X, Xue R, Luo X, Peng S, Peng H, Lu B, Tian J, Zhang Y. Potent Inhibition of Nitric Oxide-Releasing Bifendate Derivatives against Drug-Resistant K562/A02 Cells in Vitro and in Vivo. J Med Chem 2017; 60:928-940. [PMID: 28068095 DOI: 10.1021/acs.jmedchem.6b01075] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Multidrug resistance is a major obstacle to successful chemotherapy for leukemia. In this study, a series of nitric oxide (NO)-releasing bifendate derivatives (7a-n) were synthesized. Biological evaluation indicated that the most active compound (7a) produced relatively high levels of NO and significantly inhibited the proliferation of drug-resistant K562/A02 cells in vitro and in vivo. In addition, 7a induced the mitochondrial tyrosine nitration and the intracellular accumulation of rhodamine 123 by inhibiting P-gp activity in K562/A02 cells. Furthermore, 7a remarkably down-regulated AKT, NF-κB, and ERK activation and HIF-1α expression in K562/A02 cells, which are associated with the tumor cell proliferation and drug resistance. Notably, the antitumor effects were dramatically attenuated by an NO scavenger or elimination of the NO-releasing capability of 7a, indicating that NO produced by 7a contributed to, at least partly, its cytotoxicity against drug-resistant K562/A02 cells. Overall, 7a may be a potential agent against drug-resistant myelogenous leukemia.
Collapse
Affiliation(s)
- Xiaoke Gu
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , 24 Tongjiaxiang, Nanjing 210009, People's Republic of China.,Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University , Xuzhou 221004, People's Republic of China
| | - Zhangjian Huang
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , 24 Tongjiaxiang, Nanjing 210009, People's Republic of China
| | - Zhiguang Ren
- Department of Environment and Pharmacy, Tianjin Institute of Health and Environmental Medicine , Tianjin 300050, People's Republic of China
| | - Xiaobo Tang
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , 24 Tongjiaxiang, Nanjing 210009, People's Republic of China
| | - Rongfang Xue
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , 24 Tongjiaxiang, Nanjing 210009, People's Republic of China
| | - Xiaojun Luo
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , 24 Tongjiaxiang, Nanjing 210009, People's Republic of China
| | - Sixun Peng
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , 24 Tongjiaxiang, Nanjing 210009, People's Republic of China
| | - Hui Peng
- Department of Environment and Pharmacy, Tianjin Institute of Health and Environmental Medicine , Tianjin 300050, People's Republic of China
| | - Bin Lu
- Institute of Biophysics, School of Laboratory Medicine and Life Sciences, Wenzhou Medical College , Wenzhou 325035, People's Republic of China
| | - Jide Tian
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles , Los Angeles, California 90095, United States
| | - Yihua Zhang
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University , 24 Tongjiaxiang, Nanjing 210009, People's Republic of China
| |
Collapse
|
7
|
Fusi F, Durante M, Spiga O, Trezza A, Frosini M, Floriddia E, Teodori E, Dei S, Saponara S. In vitro and in silico analysis of the vascular effects of asymmetrical N,N-bis(alkanol)amine aryl esters, novel multidrug resistance-reverting agents. Naunyn Schmiedebergs Arch Pharmacol 2016; 389:1033-43. [PMID: 27351883 DOI: 10.1007/s00210-016-1266-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 06/16/2016] [Indexed: 12/11/2022]
Abstract
Asymmetrical N,N-bis(alkanol)amine aryl esters (FRA77, GDE6, and GDE19) are potent multidrug resistance (MDR) reversers. Their structures loosely remind that of the Ca(2+) antagonist verapamil. Therefore, the aim of this study was to investigate their vascular activity in vitro. Their effects on the mechanical activity of fresh and cultured rat aorta rings on Cav1.2 channel current (I Ca1.2) of A7r5 cells and their cytotoxicity on A7r5 and EA.hy926 cells were analyzed. Docking at the rat α1C subunit of the Cav1.2 channel was simulated in silico. Compounds tested were cytotoxic at concentrations >1 μM (FRA77, GDE6, GDE19) and >10 μM (verapamil) in EA.hy926 cells, or >10 μM (FRA77, GDE6, GDE19) and at 100 μM (verapamil) in A7r5 cells. In fresh rings, the three compounds partly antagonized phenylephrine and 60 mM K(+) (K60)-induced contraction at concentrations ≥1 and ≥3 μM, respectively. On the contrary, verapamil fully relaxed rings pre-contracted with both agents. In cultured rings, 10 μM GDE6, GDE19, FRA77, and verapamil significantly reduced the contractile response to both phenylephrine and K60. Similarly to verapamil, the three compounds docked at the α1C subunit, interacting with the same amino acids residues. FRA77, GDE6, and GDE19 inhibited I Ca1.2 with IC50 values 1 order of magnitude higher than that of verapamil. FRA77-, GDE6-, and GDE19-induced vascular effects occurred at concentrations that are at least 1 order of magnitude higher than those effectively reverting MDR. Though an unambiguous divergence between MDR reverting and vascular activity is of overwhelming importance, these findings consistently contribute to the design and synthesis of novel and potent chemosensitizers.
Collapse
Affiliation(s)
- F Fusi
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via A. Moro 2, 53100, Siena, Italy
| | - M Durante
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via A. Moro 2, 53100, Siena, Italy
| | - O Spiga
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, via A. Moro 2, 53100, Siena, Italy
| | - A Trezza
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, via A. Moro 2, 53100, Siena, Italy
| | - M Frosini
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via A. Moro 2, 53100, Siena, Italy
| | - E Floriddia
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy
| | - E Teodori
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy
| | - S Dei
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy
| | - S Saponara
- Dipartimento di Scienze della Vita, Università degli Studi di Siena, Via A. Moro 2, 53100, Siena, Italy.
| |
Collapse
|
8
|
Kadioglu O, Saeed ME, Valoti M, Frosini M, Sgaragli G, Efferth T. Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses. Biochem Pharmacol 2016; 104:42-51. [DOI: 10.1016/j.bcp.2016.01.014] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Accepted: 01/20/2016] [Indexed: 12/19/2022]
|
9
|
Ren Z, Gu X, Lu B, Chen Y, Chen G, Feng J, Lin J, Zhang Y, Peng H. Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells. J Cell Mol Med 2016; 20:1095-105. [PMID: 26864945 PMCID: PMC4882976 DOI: 10.1111/jcmm.12796] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Accepted: 12/22/2015] [Indexed: 01/26/2023] Open
Abstract
The development of multidrug resistance (MDR) not only actively transports a wide range of cytotoxic drugs across drug transporters but is also a complex interaction between a number of important cellular signalling pathways. Nitric oxide donors appear to be a new class of anticancer therapeutics for satisfying all the above conditions. Previously, we reported furoxan‐based nitric oxide‐releasing compounds that exhibited selective antitumour activity in vitro and in vivo. Herein, we demonstrate that bifendate (DDB)‐nitric oxide, a synthetic furoxan‐based nitric oxide‐releasing derivative of bifendate, effectively inhibits the both sensitive and MDR tumour cell viability at a comparatively low concentration. Interestingly, the potency of DDB‐nitric oxide is the independent of inhibition of the functions and expressions of three major ABC transporters. The mechanism of DDB‐nitric oxide appears to be in two modes of actions by inducing mitochondrial tyrosine nitration and apoptosis, as well as by down‐regulating HIF‐1α expression and protein kinase B (AKT), extracellular signal‐regulated kinases (ERK), nuclear factor κB (NF‐κB) activation in MDR cells. Moreover, the addition of a typical nitric oxide scavenger significantly attenuated all the effects of DDB‐nitric oxide, indicating that the cytotoxicity of DDB‐nitric oxide is as a result of higher levels of nitric oxide release in MDR cancer cells. Given that acquired MDR to nitric oxide donors is reportedly difficult to achieve and genetically unstable, compound like DDB‐nitric oxide may be a new type of therapeutic agent for the treatment of MDR tumours.
Collapse
Affiliation(s)
- Zhiguang Ren
- Department of Environment and Pharmacy, Tianjin Institute of Health and Environmental Medicine, Beijing, China.,Department of Immunology, Institute of Basic Medical Sciences, Beijing, China
| | - Xiaoke Gu
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, China.,State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
| | - Bin Lu
- School of Laboratory Medicine and Life Science, Wenzhou Medical College, Wenzhou, China
| | - Yaqiong Chen
- Department of Immunology, Institute of Basic Medical Sciences, Beijing, China.,Department of Pharmacology, China Pharmaceutical University, Nanjing, China
| | - Guojiang Chen
- Department of Immunology, Institute of Basic Medical Sciences, Beijing, China
| | - Jiannan Feng
- Department of Immunology, Institute of Basic Medical Sciences, Beijing, China
| | - Jizhen Lin
- Department of Otolaryngology, University of Minnesota Medical School, Minneapolis, MN, USA
| | - Yihua Zhang
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
| | - Hui Peng
- Department of Environment and Pharmacy, Tianjin Institute of Health and Environmental Medicine, Beijing, China.,Department of Pharmacology, China Pharmaceutical University, Nanjing, China
| |
Collapse
|
10
|
Zhang B, Zhao T, Zhou J, Qiu Q, Dai Y, Pan M, Huang W, Qian H. Design, synthesis and biological evaluation of novel triazole-core reversal agents against P-glycoprotein-mediated multidrug resistance. RSC Adv 2016. [DOI: 10.1039/c6ra02405j] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
We designed and synthesized a novel series of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) inhibitors bearing a triazolphenethyl–tetrahydroisoquinoline scaffold through click chemistry.
Collapse
Affiliation(s)
- Bo Zhang
- Center of Drug Discovery
- State Key Laboratory of Natural Medicines
- China Pharmaceutical University
- Nanjing 210009
- P. R. China
| | - Tianxiao Zhao
- Center of Drug Discovery
- State Key Laboratory of Natural Medicines
- China Pharmaceutical University
- Nanjing 210009
- P. R. China
| | - Jie Zhou
- Center of Drug Discovery
- State Key Laboratory of Natural Medicines
- China Pharmaceutical University
- Nanjing 210009
- P. R. China
| | - Qianqian Qiu
- Center of Drug Discovery
- State Key Laboratory of Natural Medicines
- China Pharmaceutical University
- Nanjing 210009
- P. R. China
| | - Yuxuan Dai
- Center of Drug Discovery
- State Key Laboratory of Natural Medicines
- China Pharmaceutical University
- Nanjing 210009
- P. R. China
| | - Miaobo Pan
- Center of Drug Discovery
- State Key Laboratory of Natural Medicines
- China Pharmaceutical University
- Nanjing 210009
- P. R. China
| | - Wenlong Huang
- Center of Drug Discovery
- State Key Laboratory of Natural Medicines
- China Pharmaceutical University
- Nanjing 210009
- P. R. China
| | - Hai Qian
- Center of Drug Discovery
- State Key Laboratory of Natural Medicines
- China Pharmaceutical University
- Nanjing 210009
- P. R. China
| |
Collapse
|
11
|
Teodori E, Dei S, Floriddia E, Perrone MG, Manetti D, Romanelli MN, Contino M, Colabufo NA. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity. ChemMedChem 2015; 10:1339-43. [DOI: 10.1002/cmdc.201500143] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Revised: 05/07/2015] [Indexed: 11/06/2022]
|
12
|
Cort A, Ozben T. Natural Product Modulators to Overcome Multidrug Resistance In Cancer. Nutr Cancer 2015; 67:411-23. [DOI: 10.1080/01635581.2015.1002624] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Aysegul Cort
- Department of Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Tomris Ozben
- Department of Biochemistry, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| |
Collapse
|
13
|
Liu B, Qiu Q, Zhao T, Jiao L, Li Y, Huang W, Qian H. 6,7-Dimethoxy-2-{2-[4-(1H-1,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as Superior Reversal Agents for P-Glycoprotein-Mediated Multidrug Resistance. ChemMedChem 2014; 10:336-44. [DOI: 10.1002/cmdc.201402463] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2014] [Indexed: 11/11/2022]
|
14
|
Gu X, Ren Z, Peng H, Peng S, Zhang Y. Bifendate-chalcone hybrids: A new class of potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Biochem Biophys Res Commun 2014; 455:318-22. [DOI: 10.1016/j.bbrc.2014.11.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Accepted: 11/07/2014] [Indexed: 01/09/2023]
|
15
|
Dei S, Coronnello M, Floriddia E, Bartolucci G, Bellucci C, Guandalini L, Manetti D, Romanelli MN, Salerno M, Bello I, Mini E, Teodori E. Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters. Eur J Med Chem 2014; 87:398-412. [PMID: 25282263 DOI: 10.1016/j.ejmech.2014.09.084] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2014] [Revised: 09/12/2014] [Accepted: 09/26/2014] [Indexed: 11/16/2022]
Abstract
As a continuation of our research on potent and efficacious P-gp-dependent multidrug resistance (MDR) reversers, several new N,N-bis(alkanol)amine aryl esters were designed and synthesized, varying the aromatic moieties or the length of the methylenic chain. The new compounds were tested on doxorubicin-resistant erythroleukemia K562 cells (K562/DOX) in the pirarubicin uptake assay, where most of the new compounds were shown to be active. In particular the asymmetrical compounds, characterized by two linkers of different length, generally showed fairly high activities as MDR reversers. Some selected compounds (isomers 15-17) were further studied by evaluating their doxorubicin cytotoxicity enhancement (reversal fold, RF) on the K562/DOX cell line. The results of both pharmacological assays indicate that compounds 16 (GDE6) and 17 (GDE19) could be interesting leads for the development of new P-gp dependent MDR modulators.
Collapse
Affiliation(s)
- Silvia Dei
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy.
| | - Marcella Coronnello
- Dipartimento di Scienze della Salute, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Elisa Floriddia
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Gianluca Bartolucci
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Cristina Bellucci
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Luca Guandalini
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Dina Manetti
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Maria Novella Romanelli
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | - Milena Salerno
- Université Paris 13, Sorbonne Paris Cité, Laboratoire CSPBAT, CNRS (UMR 7244), UFR-SMBH, 74 Rue Marcel Cachin, 93017 Bobigny, France
| | - Ivan Bello
- Université Paris 13, Sorbonne Paris Cité, Laboratoire CSPBAT, CNRS (UMR 7244), UFR-SMBH, 74 Rue Marcel Cachin, 93017 Bobigny, France
| | - Enrico Mini
- Dipartimento di Scienze della Salute, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Elisabetta Teodori
- Dipartimento NEUROFARBA-Sezione di Farmaceutica e Nutraceutica, Università di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| |
Collapse
|
16
|
Gu X, Tang X, Zhao Q, Peng H, Peng S, Zhang Y. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem Lett 2014; 24:3419-21. [DOI: 10.1016/j.bmcl.2014.05.081] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2014] [Revised: 05/12/2014] [Accepted: 05/22/2014] [Indexed: 10/25/2022]
|
17
|
Cao Z, Wright M, Cheng J, Huang X, Liu L, Wu L, Yang P. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance. Oncol Rep 2014; 32:1211-7. [PMID: 25017650 DOI: 10.3892/or.2014.3326] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Accepted: 06/18/2014] [Indexed: 11/06/2022] Open
Abstract
Multidrug resistance (MDR) to chemotherapeutic drugs is the main cause of chemotherapy failure in cancer treatment, and it generally results from expression of ATP-dependent efflux pump P-glycoprotein (P-gp). MDR reversal agents typically act by inhibiting the drug efflux activity of P-gp, thereby increasing intracellular drug levels. PY35 is a novel 5-substituted tetrandrine (Tet) derivative (CN Application No. 201210238709.6). The present study was performed to investigate the ability of PY35 to reverse P-gp-mediated MDR and its mechanism in resistant K562/Adriamycin (ADM), MCF-7/ADM cells and their sensitive cell lines K562 and MCF-7. The ability of PY35 to reverse drug resistance was evaluated by MTT assay. The results showed that PY35 can reverse MDR more effectively than the drug prototype‑Tet. The P-gp function was assessed by the Rhodamine 123 (Rho-123; a P-gp substrate) uptake assay with flow cytometry (FCM) and laser scanning confocal microscopes (LSCM); it showed that the MDR cells pumped Rho-123 out the cells, while their sensitive cells scarcely showed efflux. The presence of PY35 efficiently decreased the efflux of the Rho-123, showing that PY35 can reverse P-gp-mediated MDR by increasing the intracellular concentration of Rho-123. The intracellular accumulation of ADM was analyzed by FCM and showed that the coadministration of PY35 and ADM had clearer accumulation than the treatment of Tet and ADM, and was also more evident than treatment with only ADM. The effect of PY35 on the expression of P-gp was assessed by western blotting. The results indicated that PY35 does not inhibit the expression level of the P-gp. This study indicated that PY35 can effectively reverse P-gp-mediated MDR, not by inhibiting the expression of P-gp, but by the coadministration of PY35 and ADM that could increase the intracellular accumulation of drugs. Thus, PY35 may be a potential inhibitor to overcome drug resistance.
Collapse
Affiliation(s)
- Zhonglian Cao
- School of Pharmacy, Fudan University, Shanghai 201203, P.R. China
| | | | - Jiekai Cheng
- Hangzhou Inspiration Pharmaceutical Development Co., Ltd., Hangzhou, Zhejiang 310030, P.R. China
| | - Xiaoxing Huang
- Center for Pharmacological Evaluation and Research of SIPI, Shanghai Institute of Pharmaceutical Industry, Shanghai 200437, P.R. China
| | - Li Liu
- Center for Pharmacological Evaluation and Research of SIPI, Shanghai Institute of Pharmaceutical Industry, Shanghai 200437, P.R. China
| | - Lixing Wu
- School of Pharmacy, Fudan University, Shanghai 201203, P.R. China
| | - Ping Yang
- School of Pharmacy, Fudan University, Shanghai 201203, P.R. China
| |
Collapse
|
18
|
Orlandi F, Coronnello M, Bellucci C, Dei S, Guandalini L, Manetti D, Martelli C, Romanelli MN, Scapecchi S, Salerno M, Menif H, Bello I, Mini E, Teodori E. New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR). Bioorg Med Chem 2012; 21:456-65. [PMID: 23245571 DOI: 10.1016/j.bmc.2012.11.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2012] [Revised: 11/07/2012] [Accepted: 11/12/2012] [Indexed: 10/27/2022]
Abstract
As a continuation of previous research on a new series of potent and efficacious P-gp-dependent multidrug resistant (MDR) reversers with a N,N-bis(cyclohexanol)amine scaffold, we have designed and synthesized several analogs by modulation of the two aromatic moieties linked through ester functions to the N,N-bis(cyclohexanol)amine, aiming to optimize activity and to extend structure-activity relationships (SAR) within the series. This scaffold, when esterified with two different aromatic carboxylic acids, gives origin to four geometric isomers (cis/trans, trans/trans, cis/cis and trans/cis). The new compounds were tested on doxorubicin-resistant erythroleukemia K562 cells (K562/DOX) in the pirarubicin uptake assay. Most of them resulted in being potent modulators of the extrusion pump P-gp, showing potency values ([I](0.5)) in the submicromolar and nanomolar range. Of these, compounds 2b, 2c, 3d, 5a-d and 6d, showed excellent efficacy with a α(max) close to 1. Selected compounds (2d, 3a, 3b, 5a-d) were further studied to evaluate their doxorubicin cytotoxicity potentiation (RF) on doxorubicin-resistant erythroleukemia K562 cells and were found able to enhance significantly doxorubicin cytotoxicity on K562/DOX cells. The results of both pirarubicin uptake and the cytotoxicity assay, indicate that the new compounds of the series are potent P-gp-mediated MDR reversers. They present a structure with a mix of flexible and rigid moieties, a property that seems critical to allow the molecules to choose the most productive of the several binding modes possible in the transporter recognition site. In particular, compounds 5c and 5d, similar to the already reported analogous isomers 1c and 1d,(29) are potent and efficacious modulators of P-gp-dependent MDR and may be promising leads for the development of MDR-reversal drugs.
Collapse
Affiliation(s)
- Francesca Orlandi
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors. Eur J Med Chem 2012; 51:137-44. [DOI: 10.1016/j.ejmech.2012.02.034] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2011] [Revised: 02/11/2012] [Accepted: 02/16/2012] [Indexed: 12/18/2022]
|
20
|
Gu X, Ren Z, Tang X, Peng H, Ma Y, Lai Y, Peng S, Zhang Y. Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors. Bioorg Med Chem 2012; 20:2540-8. [PMID: 22429509 DOI: 10.1016/j.bmc.2012.02.050] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2012] [Revised: 02/21/2012] [Accepted: 02/22/2012] [Indexed: 12/31/2022]
Abstract
Overexpression of P-glycoprotein (P-gp) is one of the major problems to successful cancer chemotherapy. To find novel effective P-gp inhibitors, a series of bifendate-chalcone hybrids were synthesized and evaluated. Among them, the most active compound 8g had little intrinsic cytotoxicity (IC(50)>200 μM), and could increase accumulation of Rhodamine 123 in K562/A02 cells more potently than bifendate and verapamil (VRP) by inhibiting P-gp efflux function. And 8g displayed potent chemo-sensitizing effect and persisted for much longer time (>24h) compared with VRP (<6h). In addition, 8g, unlike VRP, showed no stimulation on the P-gp ATPase activity, suggesting it is not a P-gp substrate. Therefore, 8g may represent a promising lead to develop MDR reversal agents for cancer chemotherapy.
Collapse
Affiliation(s)
- Xiaoke Gu
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Pellicani RZ, Stefanachi A, Niso M, Carotti A, Leonetti F, Nicolotti O, Perrone R, Berardi F, Cellamare S, Colabufo NA. Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein. J Med Chem 2011; 55:424-36. [PMID: 22112208 DOI: 10.1021/jm201305y] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The multifactorial nature of chemotherapy failure in controlling cancer is often associated with the occurrence of multidrug resistance (MDR), a phenomenon likely related to the increased expression of members of the ATP binding cassette (ABC) transporter superfamily. In this respect, the most extensively characterized MDR transporters include ABCB1 (also known as MDR1 or P-glycoprotein) and ABCC1 (also known as MRP1) whose inhibition remains a priority to circumvent drug resistance. Herein, we report how the simple galloyl benzamide scaffold can be easily and properly decorated for the preparation of either MRP1 or P-gp highly selective inhibitors. In particular, some gallamides and pyrogallol-1-monomethyl ethers showed remarkable affinity and selectivity toward MRP1. On the other hand, trimethyl ether galloyl anilides, with few exceptions, exhibited moderate to very high and selective P-gp inhibition.
Collapse
Affiliation(s)
- Raffaella Zoe Pellicani
- Dipartimento Farmaco-Chimico, Università degli Studi di Bari "Aldo Moro", Via Orabona 4, 70125 Bari, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
N,N-Bis(cyclohexanol)amine aryl esters inhibit P-glycoprotein as transport substrates. Biochem Pharmacol 2011; 82:1822-31. [DOI: 10.1016/j.bcp.2011.08.025] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Revised: 08/29/2011] [Accepted: 08/30/2011] [Indexed: 11/21/2022]
|
23
|
Possidente M, Dragoni S, Franco G, Gori M, Bertelli E, Teodori E, Frosini M, Valoti M. Rat intestinal precision-cut slices as an in vitro model to study xenobiotic interaction with transporters. Eur J Pharm Biopharm 2011; 79:343-8. [DOI: 10.1016/j.ejpb.2011.04.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2010] [Revised: 03/30/2011] [Accepted: 04/11/2011] [Indexed: 12/30/2022]
|
24
|
Saponara S, Gorelli B, Tzankova V, Martelli C, Teodori E, Sgaragli G, Fusi F. The novel potent multidrug resistance inhibitors N,N-bis(cyclohexanol)amine aryl esters are devoid of vascular effects. Pharmacology 2011; 88:137-41. [PMID: 21921667 DOI: 10.1159/000330452] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2011] [Accepted: 06/16/2011] [Indexed: 11/19/2022]
Abstract
The aim of this study was to investigate the effects of the four isomers (3a, 3b, 3c and 3d) of a novel multidrug resistance-reverting agent - 3,4,5-trimethoxybenzoic acid 4-(methyl-{4-[3-(3,4,5-trimethoxyphenyl)acryloyloxy]cyclohexyl}amino)cyclohexyl ester - on vascular functions in vitro. A comparison of their mechanical and electrophysiological actions in rat aorta rings and single rat tail artery myocytes, respectively, was performed. In rat aorta rings, 3a-d antagonized both 60 mmol/l K(+)- and phenylephrine-induced contraction in a concentration-dependent manner, with maximal relaxation values averaging 50% of controls, 3d being the most effective of the series. The vasorelaxing effect was similar either in presence or absence of intact endothelium. In rat tail artery myocytes, out of the four isomers, only 3a consistently inhibited Ba(2+) current through Ca(v)1.2 channels. Our results provide functional evidence that 3a-d are weak vasorelaxing agents, although at concentrations much higher than those effective for multidrug resistance reversion in cancer cells.
Collapse
Affiliation(s)
- Simona Saponara
- Dipartimento di Neuroscienze, Università degli Studi di Siena, Siena, Italy.
| | | | | | | | | | | | | |
Collapse
|
25
|
Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev 2011; 32:1220-62. [PMID: 21374643 DOI: 10.1002/med.20239] [Citation(s) in RCA: 130] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Multidrug resistance (MDR) is a major obstacle to the effective treatment of cancer. Cellular overproduction of P-glycoprotein (P-gp), which acts as an efflux pump for various anticancer drugs (e.g. anthracyclines, Vinca alkaloids, taxanes, epipodophyllotoxins, and some of the newer antitumor drugs) is one of the more relevant mechanisms underlying MDR. P-gp belongs to the superfamily of ATP-binding cassette transporters and is encoded by the ABCB1 gene. Its overexpression in cancer cells has become a therapeutic target for circumventing MDR. As an alternative to the classical pharmacological strategy of the coadministration of pump inhibitors and cytotoxic substrates of P-gp and to other approaches applied in experimental tumor models (e.g. P-gp-targeting antibodies, ABCB1 gene silencing strategies, and transcriptional modulators) and in the clinical setting (e.g. incapsulation of P-gp substrate anticancer drugs into liposomes or nanoparticles), a more intriguing strategy for circumventing MDR is represented by the development of new anticancer drugs which are not substrates of P-gp (e.g. epothilones, second- and third-generation taxanes and other microtubule modulators, topoisomerase inhibitors). Some of these drugs have already been tested in clinical trials and, in most of cases, show relevant activity in patients previously treated with anticancer agents which are substrates of P-gp. Of these drugs, ixabepilone, an epothilone, was approved in the United States for the treatment of breast cancer patients pretreated with an anthracycline and a taxane. Another innovative approach is the use of molecules whose activity takes advantage of the overexpression of P-gp. The possibility of overcoming MDR using the latter two approaches is reviewed herein.
Collapse
Affiliation(s)
- Stefania Nobili
- Department of Preclinical and Clinical Pharmacology, University of Florence Florence, Italy, Viale Pieraccini, 6-50139, Firenze, Italy.
| | | | | | | |
Collapse
|
26
|
Martelli C, Dei S, Lambert C, Manetti D, Orlandi F, Romanelli MN, Scapecchi S, Salerno M, Teodori E. Inhibition of P-glycoprotein-mediated Multidrug Resistance (MDR) by N,N-bis(cyclohexanol)amine aryl esters: further restriction of molecular flexibility maintains high potency and efficacy. Bioorg Med Chem Lett 2010; 21:106-9. [PMID: 21145739 DOI: 10.1016/j.bmcl.2010.11.059] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2010] [Revised: 11/15/2010] [Accepted: 11/15/2010] [Indexed: 11/29/2022]
Abstract
Conformational modulation of the aryl portion of a set of N,N-bis(cyclohexanol)amine aryl esters (1a-d) that are potent Pgp-dependent MDR inhibitors has been performed. Toward this end the trans-3-(3,4,5-trimethoxyphenyl)acrylic acid present in set 1 was substituted with 3-(3,4,5-trimethoxyphenyl)propanoic and 3-(3,4,5-trimethoxyphenyl)propiolic moieties to give sets 2 and 3, respectively. While the introduction of 3-(3,4,5-trimethoxyphenyl)propanoic moiety resulted in a definite drop in potency and efficacy, esterification with 3-(3,4,5-trimethoxyphenyl)propiolic acid gave four isomers (3a-d) that maintain high potency and possess optimal efficacy. These results are discussed in terms of conformational flexibility of the different sets of compounds.
Collapse
Affiliation(s)
- Cecilia Martelli
- Dipartimento di Scienze Farmaceutiche, Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino, FI, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Castagnolo D, Contemori L, Maccari G, Avramova SI, Neri A, Sgaragli G, Botta M. From taxuspine x to structurally simplified taxanes with remarkable p-glycoprotein inhibitory activity. ACS Med Chem Lett 2010; 1:416-21. [PMID: 24900226 DOI: 10.1021/ml100118k] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2010] [Accepted: 06/28/2010] [Indexed: 01/07/2023] Open
Abstract
Three simplified "non-natural" natural taxanes, related to taxuspine X, were synthetized and assayed as P-glycoprotein (P-gp) inhibitors. One of them (6) proved to be a very efficient P-gp inhibitor with an IC50 = 7.2 × 10(-6) M. In addition, to rationalize biological data, a pharmacophoric model was built through a ligand-based approach. This model represents the first example of a pharmacophore, which describes interactions of taxanes with P-gp.
Collapse
Affiliation(s)
- Daniele Castagnolo
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Alcide de Gasperi 2, 53100 Siena, Italy
| | - Lorenzo Contemori
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Alcide de Gasperi 2, 53100 Siena, Italy
| | - Giorgio Maccari
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Alcide de Gasperi 2, 53100 Siena, Italy
| | - Stanislava I. Avramova
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Alcide de Gasperi 2, 53100 Siena, Italy
| | - Annalisa Neri
- Dipartimento di Neuroscienze, Università degli Studi di Siena, via A. Moro 2, 53100 Siena, Italy
- Istituto Toscano Tumori, via T. Alderotti 26N, 50139 Firenze, Italy
| | - Gianpietro Sgaragli
- Dipartimento di Neuroscienze, Università degli Studi di Siena, via A. Moro 2, 53100 Siena, Italy
- Istituto Toscano Tumori, via T. Alderotti 26N, 50139 Firenze, Italy
| | - Maurizio Botta
- Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Alcide de Gasperi 2, 53100 Siena, Italy
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, BioLife Science Building, Suite 333, 1900 North 12th Street, Philadelphia, Pennsylvania 19122
| |
Collapse
|
28
|
Martelli C, Coronnello M, Dei S, Manetti D, Orlandi F, Scapecchi S, Novella Romanelli M, Salerno M, Mini E, Teodori E. Structure−Activity Relationships Studies in a Series of N,N-Bis(alkanol)amine Aryl Esters as P-Glycoprotein (Pgp) Dependent Multidrug Resistance (MDR) Inhibitors. J Med Chem 2010; 53:1755-62. [DOI: 10.1021/jm9016174] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Cecilia Martelli
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Marcella Coronnello
- Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Silvia Dei
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Dina Manetti
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Francesca Orlandi
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Serena Scapecchi
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Maria Novella Romanelli
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| | - Milena Salerno
- Laboratoire de Biophysique Moléculaire, Cellulaire et Tissulaire (BioMoCeTi), UMR CNRS 7033, UMPC Université Paris 6 and Universitè Paris 13, 74 rue Marcel Cachin, 93017 Bobigny, France
| | - Enrico Mini
- Dipartimento di Farmacologia Preclinica e Clinica, Università di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy
| | - Elisabetta Teodori
- Dipartimento di Scienze Farmaceutiche, Laboratorio di Progettazione Sintesi e Studio di Eterocicli Bioattivi (HeteroBioLab), Università di Firenze, via Ugo Schiff 6, 50019 Sesto Fiorentino (FI), Italy
| |
Collapse
|
29
|
Häcker HG, Leyers S, Wiendlocha J, Gütschow M, Wiese M. Aromatic 2-(thio)ureidocarboxylic acids as a new family of modulators of multidrug resistance-associated protein 1: synthesis, biological evaluation, and structure-activity relationships. J Med Chem 2009; 52:4586-95. [PMID: 19580319 DOI: 10.1021/jm900688v] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Four series of aromatic carboxylic acids were prepared with a urea or thiourea moiety at the neighboring position to the carboxyl group and benzene or thiophene as aromatic scaffold. Using a calcein AM assay, these compounds were evaluated as inhibitors of multidrug resistance-associated protein 1 (MRP1) and selected compounds were examined toward P-glycoprotein (P-gp) as well as breast cancer resistance protein (BCRP) to assess selectivity for MRP1. Two 2-thioureidobenzo[b]thiophene-3-carboxylic acids (48, 49) were identified as particularly potent inhibitors of MRP1, with IC50 values of around 1 microM. The structural features of this new family of nontoxic MRP1 inhibitors include a (thio)urea disubstituted with preferentially two alkyl groups at the terminal nitrogen and an additional fused aromatic ring.
Collapse
Affiliation(s)
- Hans-Georg Häcker
- Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany
| | | | | | | | | |
Collapse
|